TY - JOUR
T1 - Serum antioxidant capacity and oxidative injury to pulmonary DNA in never-smokers with primary lung cancer
AU - Ito, Kensaku
AU - Yano, Tokujiro
AU - Morodomi, Yosuke
AU - Yoshida, Tsukihisa
AU - Kohno, Mikihiro
AU - Haro, Akira
AU - Shikada, Yasunori
AU - Okamoto, Tatsuro
AU - Maruyama, Riichiroh
AU - Maehara, Yoshihiko
PY - 2012/3
Y1 - 2012/3
N2 - Background/Aim: Recently, in spite of the decrease in smoking in developed nations, the prevalence of primary lung cancer has been increasing in never-smokers. In the present study, we examined the status of oxidative stress and attempted to clarify the influence of oxidative stress in non-smoking patients with lung cancer. Patients and Methods: Sixty-one lung cancer patients who underwent a surgical resection, including 27 never-smokers and 34 ever-smokers with a history of more than 20 pack-years, were included. In addition, 18 surgical patients with benign lung diseases treated during the same period were also included as non-malignant controls. Using blood samples, both serum oxidative stress (OS) and anti-oxidant capacity (AOC) were examined with the derivatives of reactive oxygen metabolites (D-Roms) test and the biological antioxidant power (BAP) test, respectively. To assess the oxidative damage of the DNA in lung tissues, the non-lesion site tissues of the lung were immunohistochemically examined for the accumulation of thymidine glycol (TG). Results: There was no significant relationship between the serum OS level and various clinicopathological factors including the patient age, sex, body mass index, pathologic stage, and smoking status. On the other hand, the mean level of AOC was significantly lower in never-smokers than in ever-smokers. Although the mean TG-positive rate in ever-smokers was significantly higher than that in never-smokers, the mean TG-positive rate of the latter was significantly higher than that of patients with benign diseases. Conclusion: The present study first demonstrated the low AOC in never-smokers with NSCLC, which may be a factor contributing to excessive oxidative DNA damage in the lung tissues.
AB - Background/Aim: Recently, in spite of the decrease in smoking in developed nations, the prevalence of primary lung cancer has been increasing in never-smokers. In the present study, we examined the status of oxidative stress and attempted to clarify the influence of oxidative stress in non-smoking patients with lung cancer. Patients and Methods: Sixty-one lung cancer patients who underwent a surgical resection, including 27 never-smokers and 34 ever-smokers with a history of more than 20 pack-years, were included. In addition, 18 surgical patients with benign lung diseases treated during the same period were also included as non-malignant controls. Using blood samples, both serum oxidative stress (OS) and anti-oxidant capacity (AOC) were examined with the derivatives of reactive oxygen metabolites (D-Roms) test and the biological antioxidant power (BAP) test, respectively. To assess the oxidative damage of the DNA in lung tissues, the non-lesion site tissues of the lung were immunohistochemically examined for the accumulation of thymidine glycol (TG). Results: There was no significant relationship between the serum OS level and various clinicopathological factors including the patient age, sex, body mass index, pathologic stage, and smoking status. On the other hand, the mean level of AOC was significantly lower in never-smokers than in ever-smokers. Although the mean TG-positive rate in ever-smokers was significantly higher than that in never-smokers, the mean TG-positive rate of the latter was significantly higher than that of patients with benign diseases. Conclusion: The present study first demonstrated the low AOC in never-smokers with NSCLC, which may be a factor contributing to excessive oxidative DNA damage in the lung tissues.
UR - http://www.scopus.com/inward/record.url?scp=84858779334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858779334&partnerID=8YFLogxK
M3 - Article
C2 - 22399633
AN - SCOPUS:84858779334
SN - 0250-7005
VL - 32
SP - 1063
EP - 1067
JO - Anticancer research
JF - Anticancer research
IS - 3
ER -